CNFWJ JOINS CUREAGE THERAPEUTICS AS A NEW VENTURE PHILANTHROPY INVESTOR

CureNFwithJack is thrilled to announce that we have joined CureAge Therapeutics as a venture philanthropy investor to help accelerate the development of next-generation genetic therapies for NF1.

“We are honored to partner with CureAge in advancing innovative gene-based approaches that have the potential to change the trajectory of neurofibromatosis. At CureNFwithJack, we believe that patients cannot wait. We are committed to investing in bold, translational science that can accelerate meaningful progress from the laboratory to patients — with urgency, with hope, and with an unwavering focus on delivering better treatments and, ultimately, a cure.”

-Elizabeth O’Brien, Co-Founder and CEO of CureNFwithJack

Read the full press release online, here: CureNFwithJack backs CureAge Therapeutics to accelerate genetic medicines for NF1